Results 41 to 50 of about 2,303 (187)

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection

Frontiers in Immunology, 2023
IntroductionNirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lower ...
Tyler Brady, Corinne Cayatte, Tiffany L. Roe, Scott D. Speer, Hong Ji, LeeAnn Machiesky, Tianhui Zhang, Deidre Wilkins, Kevin M. Tuffy, Elizabeth J. Kelly   +9 more
doaj   +1 more source

Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants. [PDF]

Pediatr Pulmonol
ABSTRACT Introduction Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long‐acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024.
Tarizzo M, Mesinèle J, Prevost B, Denamur S, Peulier-Maitre E, Guillot L, Nathan N, Corvol H.   +7 more
europepmc   +2 more sources

Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF

Expert Review of Vaccines
Background Respiratory syncytial virus (RSV) remains a leading cause of medically attended lower respiratory tract disease (MA-LRTD) among infants in Japan.
Naruhiko Ishiwada, Xinyu Wang, Takeshi Arashiro, Camille Reygrobellet, Benjamin Yarnoff, Robert Musci, Mehdi Ghemmouri   +6 more
doaj   +1 more source

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in FranceResearch in context

EClinicalMedicine
Summary: Background: To evaluate the acceptance and safety of the treatment of newborns with nirsevimab (a long-acting monoclonal antibody designed to prevent respiratory syncytial virus infections) during the first season of implementation.
Charlotte Ocana de Sentuary, Clara Testard, Marion Lagrée, Maxime Leroy, Lisa Gasnier, Alicia Enes-Dias, Constance Leruste, Diariatou Diallo, Michael Génin, Thameur Rakza, François Dubos   +10 more
doaj   +1 more source

Vaccination in pediatric transplantation—General recommendations. A position paper by the European Reference Network TransplantChild

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Infectious diseases remain a leading cause of morbidity and mortality among pediatric transplant recipients, despite significant advances in transplantation management. Vaccination is the most effective strategy to prevent infections; however, its efficacy is hindered in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT)
Valeria Casotti, Francesco Saglio, Adriana Balduzzi, Peter Barany, Vibeke Brix Christensen, Simona Buelli, Daniele Donà, Maja Klaudel‐Dreszler, Sara Mosca, Andrea Pietrobattista, Michele Pinon, Giusy Ranucci, Lars Wennberg, Lorenzo D'Antiga, ERN TransplantChild Working Group, Claudia Vittori, Manuela Tumino, B. Ruben Brandsema, Lisa Swartling, Silvia Garazzino, Carlo Pace Napoleone, Kai Lehmberg, Isabella Guzzo, Charlotte Roy, Nicola Pradegan, Silvia Simo Nebot, Maria Herthelius, Angelo Mazza, Enrico Aidala, Oleg Godik, Victoria Bordon Cueto De Braem, Marco Busutti, Emily Claire Argento, Marc Garcia Lorenzo, Timo Jahnukainen, Zoryana Ivanyuk   +35 more
wiley   +1 more source

Respiratory Syncytial Virus Vaccination Is Associated With Increased Odds of Preterm Birth

Acta Paediatrica, EarlyView.
ABSTRACT Aim To analyse whether respiratory syncytial virus (RSV) vaccination during pregnancy increases the odds of preterm birth. Methods A rapid review and meta‐analysis was performed. The main outcome was the risk of preterm (gestational week less than 37) birth.
Ilari Kuitunen, Marjut Haapanen
wiley   +1 more source

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

Acta Paediatrica, EarlyView.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner, Despina D. Briana, Gian Carlo Di Renzo   +2 more
wiley   +1 more source

Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysisResearch in context

The Lancet Regional Health. Americas
Summary: Background: In August 2023, the Centers for Disease Control and Prevention recommended nirsevimab, a long-acting monoclonal antibody, for all U.S. infants aged
Amanda B. Payne, Steph Battan-Wraith, Elizabeth A.K. Rowley, Melissa S. Stockwell, Sara Y. Tartof, Kristin Dascomb, Stephanie A. Irving, Brian Dixon, Sarah W. Ball, Mark W. Tenforde, Gabriela Vazquez-Benitez, Ashley B. Stephens, Jungmi Han, Karthik Natarajan, S. Bianca Salas, Cassandra Bezi, Lina S. Sy, Bruno Lewin, Tamara Sheffield, Julie Arndorfer, Daniel Bride, Josh Van Otterloo, Allison L. Naleway, Padma D. Koppolu, Shaun Grannis, William Fadel, Colin Rogerson, Tom Duszynski, Sarah E. Reese, Patrick K. Mitchell, Sean Chickery, Heidi L. Moline, Morgan Najdowski, Allison Avrich Ciesla, Emily L. Reeves, Malini DeSilva, Katherine E. Fleming-Dutra, Ruth Link-Gelles   +37 more
doaj   +1 more source

The New Era of Respiratory Syncytial Virus Protection for Infants: A Mini Review of Current Tools for Immunoprophylaxis

Acta Paediatrica, EarlyView.
ABSTRACT Aim This mini review describes the history of infant respiratory syncytial virus (RSV) immunoprophylaxis and the latest advances in this area. It also reviews the efficacy, safety and impact of the recently introduced prophylactic strategies. Method This narrative review is based on a targeted review of published literature, with emphasis on ...
Santtu Heinonen, Pekka Vartiainen
wiley   +1 more source

Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales [PDF]

, 2022
INTRODUCTION: Respiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease.
Koltai, Mihaly, Flasche, Stefan, Jit, Mark, Atkins, Katherine E; id_orcid, Hodgson, David, Krauer, Fabienne, Atkins, Katherine E   +6 more
core   +1 more source